201. Methotrexate treatment of cervical pregnancies with different clinical parameters. A report of three cases.
- Author
-
Hsu JJ, Chiu TH, Lai IM, and Soong YK
- Subjects
- Adult, Chorionic Gonadotropin blood, Chorionic Gonadotropin, beta Subunit, Human, Female, Humans, Peptide Fragments blood, Pregnancy, Pregnancy, Ectopic blood, Pregnancy, Ectopic diagnostic imaging, Ultrasonography, Cervix Uteri, Methotrexate therapeutic use, Pregnancy, Ectopic drug therapy
- Abstract
Three cases of cervical pregnancy with different clinical parameters were successfully treated with methotrexate. Case 1 was a viable cervical pregnancy, case 2 was a cervical pregnancy after curettage that developed into a cervical hematoma, and case 3 was a cervical pregnancy at an early gestational age. The interval between diagnosis and treatment ranged from 45 to 76 days. The maximum quantitative beta-human chorionic gonadotropin (beta-hCG) levels in cases 1, 2 and 3 were 100,180, 19,093 and 956 mIU/mL, respectively. These patients showed a progressive decline in beta-hCG levels, and ultrasound showed a gradual decrease in the size of the pregnancies. The interval between treatment and beta-hCG resolution ranged from 14 to 59 days. Only in case 2 did side effects occur, including stomatitis and transient elevation of serum transaminase. In view of the risks of standard therapy and patients' desire for fertility, methotrexate treatment may be a therapeutic alternative for cervical pregnancy.
- Published
- 1995